Aliases & Classifications for Nephrolithiasis

MalaCards integrated aliases for Nephrolithiasis:

Name: Nephrolithiasis 38 12 76 29 55 6 15 73
Nephrolithiasis, Calcium Oxalate 12
Urolithiasis, Calcium Oxalate 12
Calculus of Kidney and Ureter 12
Stone - Kidney/ureter 12
Kidney Calculi 73
Kidney Stones 12

Classifications:



External Ids:

Disease Ontology 12 DOID:585
ICD10 33 N20 N20.2
ICD9CM 35 592

Summaries for Nephrolithiasis

MalaCards based summary : Nephrolithiasis, also known as nephrolithiasis, calcium oxalate, is related to dominant hypophosphatemia with nephrolithiasis or osteoporosis and hypouricemia, renal, 1, and has symptoms including renal pain An important gene associated with Nephrolithiasis is MIF-AS1 (MIF Antisense RNA 1
Rs755622 GC/CC had a significantly increased nephrolithiasis risk compared to those with the GG genotype,indicating that the C allele has a deleterious effect on nephrolithiasis risk. The results revealed that the MIF-AS rs755622 may act as a candidate marker to predict the nephrolithiasis risk in Chinese populations. Lastly,we proposed a hypothesis that rs755622 participates in the development of nephrolithiasis by modulating the function of MIF and lncRNA MIF-AS.
Dysfunction Pattern: ), and among its related pathways/superpathways are Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds and Parathyroid hormone synthesis, secretion and action. The drugs Menthol and Tamsulosin have been mentioned in the context of this disorder. Affiliated tissues include Kidney, kidney and bone, and related phenotypes are homeostasis/metabolism and renal/urinary system

Wikipedia : 76 Kidney stone disease, also known as urolithiasis, is when a solid piece of material (kidney stone)... more...

Related Diseases for Nephrolithiasis

Diseases related to Nephrolithiasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 155)
# Related Disease Score Top Affiliating Genes
1 dominant hypophosphatemia with nephrolithiasis or osteoporosis 34.0 SLC34A1 SLC9A3R1
2 hypouricemia, renal, 1 32.6 SLC22A12 SLC2A9
3 acute urate nephropathy 32.1 SLC22A12 ZNF365
4 hypophosphatemic rickets, x-linked recessive 32.1 CLCN5 SLC34A1 SLC34A3
5 nephrolithiasis, calcium oxalate 30.8 AGXT APRT CASR CLCN5 GRHPR SLC26A1
6 hypercalciuria, absorptive, 2 30.5 CASR CLCN5 CLDN16 SLC34A3
7 fanconi syndrome 30.2 CLCN5 SLC34A1
8 hypophosphatemia 30.2 CLCN5 SLC34A1 SLC34A3
9 hereditary hypophosphatemic rickets 30.1 SLC34A1 SLC34A3
10 rickets 30.0 CLCN5 SLC34A1 SLC34A3
11 idiopathic hypercalciuria 30.0 CASR CLCN5 SLC34A3
12 pulmonary alveolar microlithiasis 29.9 SLC34A1 SLC34A3
13 nephrocalcinosis 29.7 AGXT CLCN5 CLDN16 GRHPR SLC34A1
14 gout 29.7 APRT SLC22A12 SLC2A9
15 chronic kidney failure 29.6 AGXT CASR CLDN16
16 sialolithiasis 29.4 CASR SPP1
17 bone disease 29.4 CASR SLC34A3 SPP1
18 hypophosphatemic rickets with hypercalciuria, hereditary 29.2 CLDN16 SLC34A1 SLC34A3
19 osteoporosis 29.1 CASR SLC34A1 SLC9A3R1 SPP1
20 xanthinuria 28.3 APRT CLDN16 SLC22A12 SLC2A9
21 nephrolithiasis, x-linked recessive, with renal failure 12.4
22 nephrolithiasis, uric acid 12.4
23 nephrolithiasis/osteoporosis, hypophosphatemic, 1 12.3
24 nephrolithiasis/osteoporosis, hypophosphatemic, 2 12.3
25 dent disease 1 12.0
26 adenine phosphoribosyltransferase deficiency 11.3
27 hyperglycinuria 11.3
28 renal tubular acidosis, distal 11.1
29 dent disease 2 11.0
30 renal tubular acidosis, distal, autosomal dominant 10.9
31 hypotonia-cystinuria syndrome 10.9
32 renal tubular acidosis, distal, with hemolytic anemia 10.9
33 hypouricemia, renal, 2 10.9
34 urolithiasis, uric acid, autosomal dominant 10.8
35 polycystic kidney disease 1 with or without polycystic liver disease 10.8
36 hyperoxaluria, primary, type i 10.8
37 hyperoxaluria, primary, type ii 10.8
38 renal tubular acidosis, distal, with progressive nerve deafness 10.8
39 renal tubular acidosis, distal, autosomal recessive 10.8
40 parathyroid carcinoma 10.8
41 familial primary hypomagnesemia with hypercalciuria and nephrocalcinosis 10.8
42 slc4a1-associated distal renal tubular acidosis 10.8
43 aminoaciduria 10.5 CLCN5 SLC34A1 SLC3A1
44 hypophosphatemic rickets, x-linked dominant 10.3 SLC34A1 SLC34A3
45 bartter disease 10.3 CASR CLCN5
46 kidney disease 10.1
47 phosphorus metabolism disease 10.1 CASR SLC34A1 SLC34A3
48 ureterolithiasis 10.1
49 hyperparathyroidism 10.0
50 medullary sponge kidney 10.0

Graphical network of the top 20 diseases related to Nephrolithiasis:



Diseases related to Nephrolithiasis

Symptoms & Phenotypes for Nephrolithiasis

UMLS symptoms related to Nephrolithiasis:


renal pain

MGI Mouse Phenotypes related to Nephrolithiasis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10 AGXT APRT CASR CLCN5 CLDN16 GRHPR
2 renal/urinary system MP:0005367 9.8 CASR CLCN5 CLDN16 GRHPR SLC22A12 SLC26A1
3 digestive/alimentary MP:0005381 9.73 CASR SLC22A12 SLC26A1 SLC2A9 SLC34A3 SLC9A3R1
4 skeleton MP:0005390 9.23 SLC34A3 SLC3A1 SLC9A3R1 SPP1 ZNF365 CASR

Drugs & Therapeutics for Nephrolithiasis

Drugs for Nephrolithiasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 337)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Menthol Approved Phase 4,Not Applicable 2216-51-5 16666
2
Tamsulosin Approved, Investigational Phase 4,Phase 3,Not Applicable 106133-20-4 129211
3
Lidocaine Approved, Vet_approved Phase 4,Not Applicable 137-58-6 3676
4
Allopurinol Approved Phase 4,Phase 2 315-30-0 2094
5
Benzocaine Approved, Investigational Phase 4,Not Applicable 1994-09-7, 94-09-7 2337
6
Potassium Citrate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable
7
Atropine Approved, Vet_approved Phase 4 5908-99-6, 51-55-8 174174
8
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
9
Loperamide Approved Phase 4 53179-11-6 3955
10
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 57-27-2 5288826
11
Opium Approved, Illicit Phase 4 8008-60-4
12
Ketorolac Approved Phase 4,Phase 2,Not Applicable 74103-06-3, 66635-83-4 3826
13
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
14
Losartan Approved Phase 4 114798-26-4 3961
15
Selenium Approved, Investigational, Vet_approved Phase 4,Not Applicable 7782-49-2
16
Verapamil Approved Phase 4 52-53-9 2520
17
Ropivacaine Approved Phase 4,Not Applicable 84057-95-4 71273 175805
18
Acetaminophen Approved Phase 4,Phase 3,Phase 2 103-90-2 1983
19
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
20
Remifentanil Approved Phase 4 132875-61-7 60815
21
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
22
Bupivacaine Approved, Investigational Phase 4,Phase 3,Not Applicable 2180-92-9, 38396-39-3 2474
23
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
24
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
25
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
26
Ondansetron Approved Phase 4 99614-02-5 4595
27
Pentazocine Approved, Vet_approved Phase 4 359-83-1 441278
28
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
29
Ranitidine Approved Phase 4 66357-59-3, 66357-35-5 3001055
30
Thiopental Approved, Vet_approved Phase 4 76-75-5 3000715
31
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 3,Not Applicable 76-42-6 5284603
32
Alendronate Approved Phase 4,Phase 2 121268-17-5, 66376-36-1 2088
33
Silodosin Approved Phase 4,Phase 3,Phase 2 160970-54-7
34
Cephalexin Approved, Investigational, Vet_approved Phase 4,Not Applicable 15686-71-2 27447
35
Ciprofloxacin Approved, Investigational Phase 4,Not Applicable 85721-33-1 2764
36
Nitrofurantoin Approved, Vet_approved Phase 4,Not Applicable 67-20-9 5353830
37
Sulfamethoxazole Approved Phase 4,Not Applicable 723-46-6 5329
38
Trimethoprim Approved, Vet_approved Phase 4,Not Applicable 738-70-5 5578
39
Tranexamic Acid Approved Phase 4 1197-18-8 5526
40 Mirabegron Approved Phase 4 223673-61-8 9865528
41
Lesinurad Approved, Investigational Phase 4 878672-00-5 53465279
42
Ampicillin Approved, Vet_approved Phase 4,Not Applicable 69-53-4 6249
43
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
44
Vancomycin Approved Phase 4 1404-90-6 441141 14969
45
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
46
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-14-6 5280793
47
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1406-16-2
48
Vitamin D3 Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 67-97-0 6221 5280795
49
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 77-92-9 311
50 tannic acid Approved, Nutraceutical Phase 4,Not Applicable

Interventional clinical trials:

(show top 50) (show all 329)
# Name Status NCT ID Phase Drugs
1 Comparison of Safety and Efficiency of 20w 30w Holmium Laser Device in Treatment of 1-2 cm Diameter Kidney Stones With RIRS Unknown status NCT02451319 Phase 4
2 Comparison of Safety and Efficiency of 20w and 30w Holmium Laser Device in Management of 2-3 cm Diameter Kidney Stones With Retrograde Intrarenal Surgery Unknown status NCT02443909 Phase 4
3 Quality of Life in Patients With Double Loop Ureteral Stent (JJ Silicone Hydrogel Study) Unknown status NCT02489656 Phase 4
4 Comparison of RIRS Versus PCNL Methods, According to Postoperative Pain and Analgesic Demand in 2 to 4 cm Renal Stones Unknown status NCT02430168 Phase 4
5 Is There Any Relation Between Pain and Stone Location in Retrograde Intrarenal Surgery? Unknown status NCT02430883 Phase 4
6 Naftopidil 75mg for Improving Clearance of Urinary Stones Unknown status NCT02011737 Phase 4 naftopidil 75mg
7 The Effect of Vitamin D Supplementation on Calcium Excretion in Thalassemia: a Dose Response Study Unknown status NCT01323608 Phase 4 Vitamin D3;Placebo
8 The Predictors of Successful Oral Dissolution Therapy in Radiolucent Renal Stones; A Prospective Evaluation Completed NCT02373384 Phase 4 Oral alkalinization (Potassium citrate, Allopurinol)
9 Efficacy of Potassium Sodium Hydrogen Citrate Therapy on Renal Stone Recurrence and/or Residual Fragments After Shockwave Lithotripsy and Percutaneous Nephrolithotomy in Calcium Oxalate Urolithiasis Completed NCT01329042 Phase 4 Potassium-sodium citrate
10 The Use of Belladonna and Opium Suppository in the Treatment of Postoperative Stent Pain Completed NCT03332056 Phase 4 Belladonna and Opium
11 Vitamin D Repletion in Stone Formers With Hypercalciuria Completed NCT01295879 Phase 4 Ergocalciferol
12 Intravenous Ketorolac for Postoperative Pain in Percutaneous Nephrolithotomy Completed NCT00765128 Phase 4 Ketorolac;Placebo
13 Study of Tomography of Nephrolithiasis Evaluation Completed NCT01451931 Phase 4
14 Are There Protective Effects of Antioxidants, Calcium Channel Blocker and Angiotensin Receptor Blocker Against Extracorporeal Shockwaves Lithotripsy Induced Renal Injury? Completed NCT01675362 Phase 4 Antioxidant group;Calcium Channel Blockers;Angiotensin receptor blocker group;Placebo
15 Ultrasound-guided Transmuscular Quadratus Lumborum Block for Percutaneous Nephrolithotomy Completed NCT02818140 Phase 4 Ropivacaine;Saline
16 Efficacy Study of Different Analgesic Options in Kidney Stone Pain Management Completed NCT02187614 Phase 4 Diclofenac;Morphine;Paracetamol;Placebos
17 Remifentanil in Extracorporeal Shock Wave Lithotripsy Completed NCT01452880 Phase 4 Remifentanil;Remifentanil
18 Comparison Between Tramadol Hcl and Other Analgesics in the Treatment of Renal Colic Completed NCT00310908 Phase 4 Tramadol Hcl
19 Tamsulosin for Urolithiasis in the Emergency Dept Completed NCT00382265 Phase 4 tamsulosin
20 Segmental Epidural Anesthesia (SEA) V/S General Anesthesia for PCNL Completed NCT02878512 Phase 4
21 Ultrasound Guided Thoracic Paravertebral Block for Percutaneous Nephrolithotomy Operations in Children Completed NCT02291692 Phase 4
22 The Comparison of Low Thoracic Paravertebral Block Versus Peritubal Infiltration Completed NCT02764008 Phase 4 Bupivacaine
23 Therapeutic Merit of Solifenacin in the Mitigation of Ureteral Stent-induced Pain and Lower Urinary Tract Symptoms Completed NCT01381120 Phase 4 Solifenacin succinate treatment;Oxycodone and acetaminophen combination treatment
24 VITamine D Supplementation in RenAL Transplant Recipients - VITALE Completed NCT01431430 Phase 4 Cholecalciferol 100 000 UI;Cholecalciferol 12 000 UI
25 Assessment of Response to Treatment of Osteoporosis With Oral Bisphosphonates in Patients With Muscular Dystrophy Completed NCT01882400 Phase 4 Bisphosphonate treatment
26 Study Evaluating Safety And Efficacy Of Moroctocog Alfa (AF-CC) In Previously Treated Hemophilia A Patients Completed NCT00914459 Phase 4
27 Struvite Stones Antibiotic Study Recruiting NCT02375295 Phase 4 ciprofloxacin, cotrimoxazole-trimethoprim, macrodantin
28 Impact of Tranexamic Acid Use in Percutaneous Nephrolithotomy Recruiting NCT02966236 Phase 4 Tranexamic Acid;Placebos
29 Ureteral Stent-related Pain and Mirabegron (SPAM) Trial Recruiting NCT02095665 Phase 4 Mirabegron;Tamsulosin;Tylenol #3
30 Alkalinization by Urologists & Nephrologists Recruiting NCT03035812 Phase 4 Alkali
31 A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment Recruiting NCT03226899 Phase 4 Lesinurad;XOI;Placebo
32 A Randomized Trial of Preoperative Prophylactic Antibiotics Prior to Kidney Stone Surgery (Percutaneous Nephrolithotomy [PCNL]) Active, not recruiting NCT02384200 Phase 4 nitrofurantoin monohydrate/macrocrystalline capsules;ampicillin;gentamicin;vancomycin;ceftriaxone
33 Trial of Tadalafil, Tamsulosin and Combination for Access Sheath Deployment Enrolling by invitation NCT03229889 Phase 4 Cialis 5Mg Tablet;Flomax 0.4Mg Capsule;Placebo
34 Pre-induction Analgesia: Multimodel Regimen vs Aceteminophen for Post Ureteroscopy Pain Not yet recruiting NCT03549611 Phase 4 Multimodal Oral Drug Regimen;Acetaminophen
35 Trial of High Dose Vitamin D in Patient's With Crohn's Disease Terminated NCT02208310 Phase 4 Cholecalciferol 10,000 IU;Cholecalciferol 400 IU
36 Silodosin Versus Tamsulosin for Treatment of Ureteral Stones Terminated NCT02369744 Phase 4 Silodosin;Tamsulosin
37 Use of a Ureteral Access Sheath During Ureteroscopy and Its Effect on Stone Free Rate Terminated NCT00199524 Phase 4
38 The Use of Intranasal Ketoralac for Pain Management Terminated NCT01736358 Phase 4 Intranasal Ketoralac;Placebo
39 Effects of the Use of Adjuvant Drugs After Extracorporeal Shockwave Lithotripsy (ESWL) in Renal Calculus Unknown status NCT01215708 Phase 3 Tamsulosin
40 Extracorporeal Shock Wave Lithotriptor Indicated for Fragmenting Urinary Stones in the Kidney Unknown status NCT00959153 Phase 3
41 Alfuzosin for Medical Expulsion Therapy of Ureteral Stones Unknown status NCT00713739 Phase 3 Alfuzosin;nifedipine;doxazosin;prazosin
42 ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot Study Unknown status NCT02155803 Phase 2, Phase 3 ACTHAR Gel (adrenocorticotropic hormone)
43 Renalof in the Dissolution of Renal Calculi in Patients With Recurrent Calcic Lithiasis Completed NCT01022060 Phase 3
44 Low Salt Diet in Idiopathic Hypercalciuria Completed NCT01005082 Phase 2, Phase 3
45 Visceral Pain From the Upper Urinary Tract - a Trial on the Effect of Morphine and Oxycodone in Patients Undergoing PCNL Completed NCT00784472 Phase 3 oxycodone;morphine
46 Pharmacological Modulation of the Intrarenal Pressure During Endourological Procedures in the Upper Urinary Tract Completed NCT00428428 Phase 2, Phase 3 Isoproterenol
47 Phase III Randomized, Double-Blind Study of Potassium Phosphate Vs Potassium Citrate for Absorptive Hypercalciuria Completed NCT00004284 Phase 3 potassium citrate;potassium phosphate
48 Alfuzosin Hydrochloride to Promote Passage of Distal Ureteral Calculi Completed NCT00177086 Phase 3
49 The StoneBreakerTM Trial Completed NCT00677196 Phase 3
50 Trial Of Paricalcitol and Cholecalciferol(Vitamin D3) in the Treatment Of Secondary Hyperparathyroidism in Patients After ROUX-EN-Y Gastric Bypass Surgery Completed NCT01138475 Phase 3 Paricalcitol;Cholecalciferol;Placebo

Search NIH Clinical Center for Nephrolithiasis

Genetic Tests for Nephrolithiasis

Genetic tests related to Nephrolithiasis:

# Genetic test Affiliating Genes
1 Nephrolithiasis 29

Anatomical Context for Nephrolithiasis

MalaCards organs/tissues related to Nephrolithiasis:

41
Kidney, Bone, Testes, Prostate, Liver, Colon, Heart
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Nephrolithiasis:
# Tissue Anatomical CompartmentCell Relevance
1 Kidney Proximal Tubule Proximal Tubule Cells Potential therapeutic candidate, affected by disease

Publications for Nephrolithiasis

Articles related to Nephrolithiasis:

(show top 50) (show all 800)
# Title Authors Year
1
Risk of Nephrolithiasis in Patients With Sleep Apnea: A Population-Based Cohort Study. ( 29734978 )
2018
2
Lack of evidence that nephrolithiasis increases the risk of sialolithiasis: A longitudinal follow-up study using a national sample cohort. ( 29698468 )
2018
3
Claudins and nephrolithiasis. ( 29782346 )
2018
4
A novel mutation of Dent's disease in an 11-year-old male with nephrolithiasis and nephrocalcinosis. ( 29756720 )
2018
5
Pediatric nephrolithiasis: a systematic approach from diagnosis to treatment. ( 29680873 )
2018
6
The accuracy and prognostic value of point-of-care ultrasound for nephrolithiasis in the emergency department: A Systematic Review and Meta-Analysis. ( 29427476 )
2018
7
Beginnings of nephrolithiasis: insights into the past, present and future of Randall's plaque formation research. ( 29697409 )
2018
8
Current opinions on nephrolithiasis associated with primary hyperparathyroidism. ( 29350243 )
2018
9
Is sodium thiosulfate an effective treatment for recurrent calcium nephrolithiasis? Pro and con arguments. ( 29948862 )
2018
10
Study of Urine Composition of Patients With Recurrent Nephrolithiasis in Lorestan, Iran. ( 29421773 )
2018
11
Follow-up imaging after acute evaluations for pediatric nephrolithiasis: Trends from a National database. ( 29866410 )
2018
12
Race- and Sex-related Differences in Nephrolithiasis Risk Among Blacks and Whites in the Southern Community Cohort Study. ( 29753847 )
2018
13
Understanding the gut-kidney axis in nephrolithiasis: an analysis of the gut microbiota composition and functionality of stone formers. ( 29705728 )
2018
14
Influence of BMI in nephrolithiasis in an Appalachian pediatric population: A single-center experience. ( 29887297 )
2018
15
Uric acid nephrolithiasis: An update. ( 29687761 )
2018
16
Hypercalciuria and nephrolithiasis: Expanding the renal phenotype of Donnai-Barrow syndrome. ( 29532936 )
2018
17
The clinical efficacy of dual lumen catheter technique in retrograde intrarenal surgery for the management of nephrolithiasis: a propensity score analysis. ( 29316803 )
2018
18
Nephrolithiasis in a 17 Year Old Male with Seckel Syndrome and Horseshoe Kidneys: Case Report and Review of the Literature. ( 29894776 )
2018
19
Genetic polymorphisms of human transcription factor-7 like 2 (TCF7L2), I^-defensin (DEFB1) and CD14 genes in nephrolithiasis patients. ( 29959006 )
2018
20
Nephrolithiasis and Nephrocalcinosis in Childhood-Risk Factor-Related Current and Future Treatment Options. ( 29707529 )
2018
21
Calcium-sensing receptor gene polymorphism (rs7652589) is associated with calcium nephrolithiasis in the population of Yi nationality in Southwestern China. ( 29682741 )
2018
22
Having rs1042636C677T calcium-sensing receptor polymorphism: Increased or decreased risk for nephrolithiasis? ( 29970760 )
2018
23
Stones: Individual gut microbiome in nephrolithiasis. ( 29434367 )
2018
24
Nephrolithiasis and Nephrocalcinosis FromA Topiramate Therapy in Children WithA Epilepsy. ( 29854977 )
2018
25
Mucin 4 Gene Silencing Reduces Oxidative Stress and Calcium Oxalate Crystal Formation in Renal Tubular Epithelial Cells Through the Extracellular Signal-Regulated Kinase Signaling Pathway in Nephrolithiasis Rat Model. ( 29843125 )
2018
26
Surgical Management of Nephrolithiasis in the Bottlenose Dolphin: Collaborations Between the Urologist and Veterinarian. ( 29756043 )
2018
27
Inflammatory Cytokines in the Papillary Tips and Urine of Nephrolithiasis Patients. ( 29338314 )
2018
28
Nephrolithiasis and risk of hypertension: a meta-analysis of observational studies. ( 29187160 )
2017
29
Lifetime Radiation Exposure in Patients with Recurrent Nephrolithiasis. ( 28900827 )
2017
30
Association of MMP-9 gene polymorphisms with nephrolithiasis patients. ( 28205286 )
2017
31
A 10-Year Retrospective Review of Nephrolithiasis in the Navy and Navy Pilots. ( 28235550 )
2017
32
PDE1A polymorphism contributes to the susceptibility of nephrolithiasis. ( 29262781 )
2017
33
Metabolic investigation in patients with nephrolithiasis. ( 29267427 )
2017
34
Adherence to the Mediterranean Dietary Pattern and Incidence of Nephrolithiasis in the Seguimiento Universidad de Navarra Follow-up (SUN) Cohort. ( 28838765 )
2017
35
Ultralow Radiation Exposure During Flexible Ureteroscopy in Patients With Nephrolithiasis-How Far Can We Go? ( 28648966 )
2017
36
Nephrolithiasis: A complication of pediatric diabetic ketoacidosis. ( 28737266 )
2017
37
Marked increase in urinary excretion of apolipoproteins in children with nephrolithiasis associated with hypercalciuria. ( 28188435 )
2017
38
Non-alcoholic fatty liver disease and the development of nephrolithiasis: A cohort study. ( 29073130 )
2017
39
Re: Progress in Understanding the Genetics of Calcium-Containing Nephrolithiasis. ( 28505913 )
2017
40
Nephrolithiasis associated with the use of topiramate in children. ( 29226837 )
2017
41
Pseudomonas aeruginosa as an Etiologic Agent of Nephrolithiasis in Deep Water Divers. ( 28164160 )
2017
42
Dietary cation-anion difference may explain why ammonium urate nephrolithiasis occurs more frequently in common bottlenose dolphins () under human care than in free-ranging common bottlenose dolphins. ( 28380506 )
2017
43
Whole exome sequencing frequently detects a monogenic cause in early onset nephrolithiasis andA nephrocalcinosis. ( 28893421 )
2017
44
Response to: A role for thiazide diuretic therapy in preventing bone loss, fracture and nephrolithiasis in individuals with thalassemia and hypercalciuria? ( 28194475 )
2017
45
Development of Nephrolithiasis in Asymptomatic Hyperuricemia: A Cohort Study. ( 28410765 )
2017
46
Refining Diagnostic Approaches in Nephrolithiasis: Incomplete Distal Renal Tubular Acidosis. ( 28775128 )
2017
47
Postmenopausal hormone and the risk of nephrolithiasis: A meta-analysis. ( 28900379 )
2017
48
The Relationship Between Nephrolithiasis Risk with Body Fat Measured by Body Composition Analyzer in Obese People. ( 28883679 )
2017
49
Nephrolithiasis and Osteomalacia associated with adefovir-induced Fanconi syndrome in a patient with hepatitis B. ( 28851305 )
2017
50
Association Between Sonographically Diagnosed Nephrolithiasis and Subclinical Coronary Artery CalcificationA inA Adults. ( 28823586 )
2017

Variations for Nephrolithiasis

ClinVar genetic disease variations for Nephrolithiasis:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 46;X;t(X;5)(q24;q13)dn Translocation Pathogenic
2 MT-CO3 NC_012920.1: m.9355A> T single nucleotide variant Uncertain significance GRCh37 Chromosome MT, 9355: 9355
3 MT-CO3 NC_012920.1: m.9355A> T single nucleotide variant Uncertain significance GRCh38 Chromosome MT, 9355: 9355

Expression for Nephrolithiasis

Search GEO for disease gene expression data for Nephrolithiasis.

Pathways for Nephrolithiasis

GO Terms for Nephrolithiasis

Cellular components related to Nephrolithiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.8 CASR CLCN5 SLC22A12 SLC26A1 SLC2A9 SLC34A1
2 basolateral plasma membrane GO:0016323 9.5 CASR SLC26A1 SLC2A9
3 vesicle GO:0031982 9.46 SLC34A1 SLC34A3 SLC9A3R1 SPP1
4 apical plasma membrane GO:0016324 9.43 CASR SLC22A12 SLC2A9 SLC34A1 SLC34A3 SLC9A3R1
5 brush border membrane GO:0031526 9.02 SLC22A12 SLC34A1 SLC34A3 SLC3A1 SLC9A3R1

Biological processes related to Nephrolithiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane transport GO:0055085 9.85 CLCN5 SLC22A12 SLC26A1 SLC2A9 SLC34A3
2 ion transport GO:0006811 9.63 CLCN5 CLDN16 SLC22A12 SLC26A1 SLC34A1 SLC34A3
3 cellular nitrogen compound metabolic process GO:0034641 9.48 AGXT GRHPR
4 urate transport GO:0015747 9.43 SLC22A12 SLC2A9
5 phosphate ion transport GO:0006817 9.4 SLC34A1 SLC34A3
6 urate metabolic process GO:0046415 9.37 SLC22A12 SLC2A9
7 glyoxylate metabolic process GO:0046487 9.32 AGXT GRHPR
8 sodium-dependent phosphate transport GO:0044341 9.26 SLC34A1 SLC34A3
9 excretion GO:0007588 9.13 CLCN5 CLDN16 GRHPR
10 cellular phosphate ion homeostasis GO:0030643 8.8 SLC34A1 SLC34A3 SLC9A3R1

Molecular functions related to Nephrolithiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein homodimerization activity GO:0042803 9.77 AGXT CASR GRHPR SLC34A1 ZNF365
2 PDZ domain binding GO:0030165 9.43 SLC22A12 SLC34A1 SLC9A3R1
3 amino acid binding GO:0016597 9.32 AGXT CASR
4 urate transmembrane transporter activity GO:0015143 9.16 SLC22A12 SLC2A9
5 sodium:phosphate symporter activity GO:0005436 8.96 SLC34A1 SLC34A3
6 sodium-dependent phosphate transmembrane transporter activity GO:0015321 8.62 SLC34A1 SLC34A3

Sources for Nephrolithiasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....